• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 3. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 4. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Introduction to 3,6-Diiodo-1H-indazole (CAS No. 319472-78-1)

3,6-Diiodo-1H-indazole, with the chemical identifier CAS No. 319472-78-1, is a halogenated heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the indazole class, characterized by a fused benzene and pyrrole ring system, with the presence of two iodine atoms at the 3rd and 6th positions. The structural features of 3,6-Diiodo-1H-indazole make it a versatile intermediate in organic synthesis, particularly in the development of bioactive molecules.

The indazole scaffold is a privileged structure in drug discovery, owing to its ability to interact with various biological targets. The introduction of iodine atoms at specific positions enhances the reactivity of the molecule, making it a valuable precursor for further functionalization. In recent years, 3,6-Diiodo-1H-indazole has been explored in the synthesis of novel therapeutic agents, including kinase inhibitors and antimicrobial compounds.

One of the most compelling aspects of 3,6-Diiodo-1H-indazole is its role in medicinal chemistry as a building block for more complex structures. The presence of iodine atoms allows for palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Stille couplings, which are widely used in the construction of biaryl compounds. These reactions are particularly useful in generating molecules with enhanced pharmacological properties.

Recent studies have highlighted the potential of 3,6-Diiodo-1H-indazole in the development of small-molecule inhibitors targeting cancer-related kinases. For instance, researchers have demonstrated that derivatives of this compound can exhibit inhibitory activity against tyrosine kinases, which are overexpressed in many oncogenic pathways. The halogenated indazole core provides a scaffold that can be modified to optimize binding affinity and selectivity.

The synthesis of 3,6-Diiodo-1H-indazole typically involves halogenation reactions on an indazole precursor. Advanced synthetic methodologies have been developed to achieve regioselective iodination, ensuring that the iodine atoms are incorporated at the desired positions. These methods often employ catalytic systems that minimize side reactions, thereby improving yield and purity.

In addition to its applications in oncology research, 3,6-Diiodo-1H-indazole has been investigated for its antimicrobial properties. The halogenated indazole structure disrupts bacterial cell wall synthesis and inhibits essential enzymatic pathways. Preliminary studies suggest that derivatives of this compound may offer promising leads for novel antibiotics against drug-resistant strains.

The pharmacokinetic profile of 3,6-Diiodo-1H-indazole and its derivatives is another area of active investigation. Researchers are exploring ways to enhance bioavailability and reduce metabolic degradation by incorporating structural modifications such as fluorine substitution or changes in ring size. These efforts aim to develop more effective therapeutic agents with improved clinical outcomes.

The role of computational chemistry in designing novel derivatives of 3,6-Diiodo-1H-indazole cannot be overstated. Molecular modeling techniques allow researchers to predict binding interactions between the compound and biological targets with high precision. This approach accelerates the drug discovery process by enabling rational design of lead compounds before experimental validation.

Future directions in the study of 3,6-Diiodo-1H-indazole include exploring its potential in other therapeutic areas such as neurodegenerative diseases and inflammatory disorders. The versatility of the indazole scaffold and the reactivity provided by halogen atoms make it an attractive candidate for further exploration.

In conclusion, 3,6-Diiodo-1H-indazole (CAS No. 319472-78-1) represents a significant advancement in pharmaceutical chemistry as a versatile intermediate for drug development. Its structural features and reactivity make it a valuable tool for synthesizing novel bioactive molecules with potential applications across multiple therapeutic domains.

• 66607-27-0(3-Iodo-1H-indazole)
• 351456-45-6(5-Chloro-3-iodo-1H-indazole)
• 261953-36-0(6-Iodo-1H-indazole)
• 503045-59-8(6-Chloro-3-iodo-1H-indazole)
• 858629-06-8(5-Fluoro-3-iodo-1H-indazole)
• 351456-48-9(3,5-Diiodo-1H-indazole)
• 459133-66-5(5-Bromo-3-iodo-1H-indazole)
• 885518-92-3(3-Iodo-5-methyl-1H-indazole)
• 55919-82-9(5-Iodo-1H-indazole)
• 599183-36-5(3-Iodo-1H-indazol-5-amine)